martin you are correct. Without adding additional pharmacists and staff, one pharmacy can only fill so many Rxs. But even if we maintain or average $4M each month, that's a $48M annual run rate and I am sure would greatly impact SCRC's financials attracting more investors to SCRC. It will be interesting to learn what Mr. Schneiderman has planned to expand this very profitable revenue stream. I also don't believe RapiMeds is on "indefinite hold" and will soon begin impacting the bottom line in the months to follow. Mr. Schneiderman spoke about the potential for RapiMeds on his interview as well it was discussed in the most recent 10K. Things are definitely going to get exciting for all of us over the next several months. Our patience will be rewarded.